India could be staring at a national health crisis in the backdrop of its continuing massive reliance on Chinese active pharmaceutical ingredients (APIs), including those used in drugs for high-burden diseases such as diabetes and cardiovascular ailments, according to a report by the professional services firm KPMG and the Confederation of Indian Industry (CII).
China API Juggernaut Rolls On But Can India Recoup?
Report: India’s huge dependence on Chinese active pharmaceutical ingredients (APIs), including in high disease burden areas, poses heightened risks to its health security and requires “urgent interventions.”
More from Manufacturing
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.
• By
Trump announced a 26% reciprocal tariff on India but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms and the US consumer are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?
• By
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
More from Business
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.